Zycov-d Vaccine

The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

ZyCoV-D is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 years and above got approval yesterday, said it hopes to produce one crore doses per month by October.

Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.

Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose Covid shot that is the "world's first Plasmid DNA vaccine". The shot is "needle-free", says the company, and "safe for children".

An approval for Zydus' vaccine, ZyCoV-D, would make it the fifth vaccine authorized for use in the country.

Zydus Cadila has applied for Emergency Use Authorization to the office of Drug Controller General of India for ZyCoV-D - its Plasmid DNA vaccine against COVID-19

Indian drugmaker Zydus Cadila said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.

Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.

Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially.

Coronavirus vaccine: Early-stage Phase 1 and 2 human trials are likely to be concluded in the next three months

Approval for human clinical trials for two made-in-India COVID-19 vaccine candidates - COVAXIN and ZyCov-D - marks the "beginning of the end" for the novel coronavirus pandemic, the government said on Sunday

The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

ZyCoV-D is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 years and above got approval yesterday, said it hopes to produce one crore doses per month by October.

Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.

Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose Covid shot that is the "world's first Plasmid DNA vaccine". The shot is "needle-free", says the company, and "safe for children".

An approval for Zydus' vaccine, ZyCoV-D, would make it the fifth vaccine authorized for use in the country.

Zydus Cadila has applied for Emergency Use Authorization to the office of Drug Controller General of India for ZyCoV-D - its Plasmid DNA vaccine against COVID-19

Indian drugmaker Zydus Cadila said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.

Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.

Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially.

Coronavirus vaccine: Early-stage Phase 1 and 2 human trials are likely to be concluded in the next three months

Approval for human clinical trials for two made-in-India COVID-19 vaccine candidates - COVAXIN and ZyCov-D - marks the "beginning of the end" for the novel coronavirus pandemic, the government said on Sunday